(Q35164717)

6 August 2017

1 reference

title

Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder (English)

1 reference

attention deficit hyperactivity disorder

6 August 2017

1 reference

1 reference

1 reference

1 reference

based on heuristic

inferred from title

author name string

Christopher J Kratochvil

1

1 reference

6 August 2017

Brigette S Vaughan

2

1 reference

6 August 2017

Martin J Harrington

3

1 reference

6 August 2017

William J Burke

4

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

Expert Opinion on Pharmacotherapy

6 August 2017

published in

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

7

1 reference

6 August 2017

page(s)

1165-1174

1 reference

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1165

Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1165

A review of stimulant drug research with hyperactive children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1165

A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1165

Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1165

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1165

Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1165

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1165

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1165

Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1165

Parent and Teacher Ratings of ADHD Symptoms: Psychometric Properties in a Community-Based Sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.7.1165

10.1517/14656566.4.7.1165

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference